R&D PROGRAMS

Program Overview

Ministry in charge
Program duration
2021~2030 (10 years)

Performance Goals

Program

Program Details

1 Development of basic technology in regenerative medicine TRL 1~3 Development of basic technology in regenerative medicine
Category Details
Future RM basic
technology
  • Purpose : To develop promising source technologies including convergence of biocompatible materials, in vivo cell transformation, and biomaterial-cell complex
  • Duration : 3+2 years(2-staged)
  • Target technologies
    • (1) Artificial cell tissues and xenogeneic organs development technology
    • (2) Bio-reprogramming treatment technology
    • (3) Biocompatible enhancement technology
Next generation
candidate treatment
technology
  • Purpose : To develop basic RM technology including cell differentiation/maintenance/efficiency improvement technology, organoids, and cell activation technology
  • Duration : 3+2 years(2-staged), 3 years
  • Target technologies
    • (1) Diversification and advancement of the cell differentiation technology
    • (2) Technology for securing multicellular therapies
    • (3) Endogenous stem cell activation technology
Category
Future RM basic technology
Details
  • Purpose : To develop promising source technologies including convergence of biocompatible materials, in vivo cell transformation, and biomaterial-cell complex
  • Duration : 3+2 years(2-staged)
  • Target technologies
    • (1) Artificial cell tissues and xenogeneic organs development technology
    • (2) Bio-reprogramming treatment technology
    • (3) Biocompatible enhancement technology
Category
Next generation candidate treatment technology
Details
  • Purpose : To develop basic RM technology including cell differentiation/maintenance/efficiency improvement technology, organoids, and cell activation technology
  • Duration : 3+2 years(2-staged), 3 years
  • Target technologies
    • (1) Diversification and advancement of the cell differentiation technology
    • (2) Technology for securing multicellular therapies
    • (3) Endogenous stem cell activation technology

Program Details

2 Development of translational technology in regenerative medicine TRL 3~5 Development of translational technology in regenerative medicine
Category Details
Next generation
regenerative medicine
applied technology
(Technological convergence)
  • Purpose : To develop applied RM treatment and technology for verification purpose
  • Duration : 3 years
  • Target technologies
    • (1) Cell-based disease model technology
    • (2) Cell-based drug development application technology
    • (3) Organoid advancement and utilization technology
RM treatment technology
(Technology advancement)
  • Purpose : To accelerate disease-targeting non-clinical RM treatment and technology to clinical stage
  • Duration : 3+1 years(2-staged), 2 years
  • Target disorders
    • (1) Musculoskeletal disorders
    • (2) Nervous system disorders
    • (3) Circulatory and respiratory disorders
    • (4) Endocrine system disorders
    • (5) Digestive system disorders
    • (6) Other incurable disorders
Category
Next generation regenerative medicine applied technology(Technological convergence)
Details
  • Purpose : To develop applied RM treatment and technology for verification purpose
  • Duration : 3 years
  • Target technologies
    • (1) Cell-based disease model technology
    • (2) Cell-based drug development application technology
    • (3) Organoid advancement and utilization technology
Category
RM treatment technology
(Technology advancement)
Details
  • Purpose : To accelerate disease-targeting non-clinical RM treatment and technology to clinical stage
  • Duration : 3+1 years(2-staged), 2 years
  • Target disorders
    • (1) Musculoskeletal disorders
    • (2) Nervous system disorders
    • (3) Circulatory and respiratory disorders
    • (4) Endocrine system disorders
    • (5) Digestive system disorders
    • (6) Other incurable disorders

Program Details

3 Development of RM treatment and technology TRL 6~7 Development of RM treatment and technology
Category Details
Sponsor Initiated Trials
(SIT)
  • Purpose : To complete phase 2 clinical trial of disease-targeting RM treatment through MFDS IND approval
  • Duration : 3 years
  • Target disorders
    • (1) Musculoskeletal disorders
    • (2) Nervous system disorders
    • (3) Circulatory and respiratory disorders
    • (4) Endocrine system disorders
    • (5) Digestive system disorders
    • (6) Other incurable disorders
Category
Sponsor Initiated Trials(SIT)
Details
  • Purpose : To complete phase 2 clinical trial of disease-targeting RM treatment through MFDS IND approval
  • Duration : 3 years
  • Target disorders
    • (1) Musculoskeletal disorders
    • (2) Nervous system disorders
    • (3) Circulatory and respiratory disorders
    • (4) Endocrine system disorders
    • (5) Digestive system disorders
    • (6) Other incurable disorders

Commercialization

Seoul City Tower fl.17, 110 Huam-ro, Jung-gu, Seoul 04637, Republic of Korea

Tel : +82-2-6263-3060 / Fax : +82-2-6263-3080

Copyright © KFRM. All Rights Reserved.